Compare
Regencell Bioscience Holdings Ltd vs TFA Therapeutics, Inc. vs Functional Brands Inc. vs Synergy CHC Corp.
| Latest fiscal year | Regencell Bioscience Holdings Ltd RGC | TFA Therapeutics, Inc. RAJAF | Functional Brands Inc. MEHA | Synergy CHC Corp. SNYRQ |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.25M | $6.61M | $30.38M |
| Revenue growth (YoY) | n/a | -0.6% | +0.7% | -12.8% |
| Gross margin | n/a | 61.1% | 52.7% | 66.8% |
| Operating margin | n/a | -11.3% | -21.2% | -27.8% |
| Net margin | n/a | -12.4% | 11.5% | -40.6% |
| Net income | -$3.58M | -$154.8K | $758.5K | -$12.34M |
| EPS (Diluted) | -$0.72 | $0.00 | $0.01 | -$1.27 |
| Operating cash flow | -$3.11M | -$35.8K | -$1.27M | -$2.59M |
| Free cash flow | -$3.27M | n/a | -$1.28M | n/a |
| Cash & equivalents | n/a | $3.2K | $2.73M | $2.62M |
| Total assets | $5.76M | $4.66M | $9.11M | $10.16M |
| Total liabilities | $895.3K | $5.19M | $7.57M | $33.29M |
| Shareholders' equity | $4.86M | -$534.6K | $1.54M | -$23.13M |
| Return on year-end equity | -73.7% | n/a | 49.2% | n/a |
| Shares outstanding | 494.49M | 111.12M | 18.70M | 11.30M |
Revenue, most recent five fiscal years
| Fiscal year | Regencell Bioscience Holdings Ltd | TFA Therapeutics, Inc. | Functional Brands Inc. | Synergy CHC Corp. |
|---|---|---|---|---|
| Latest | n/a | $1.25M Ended 2025-12-31 | $6.61M Ended 2025-12-31 | $30.38M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.25M Ended 2024-12-31 | $6.57M Ended 2024-12-31 | $34.83M Ended 2024-12-31 |
| 2 years earlier | n/a | $882.5K Ended 2023-12-31 | n/a | $42.78M Ended 2023-12-31 |
| 3 years earlier | n/a | $53.3K Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $879.3K Ended 2021-12-31 | n/a | n/a |